Publications by authors named "M Ozbalak"
Thrombotic thrombocytopenic purpura (TTP) is one of the rare group disorders classified as thrombotic microangiopathies (TMAs). Approximately 90% of TTP developed immune-mediation by the formation of antibodies against the enzyme ADAMTS-13. The exact cause is unknown.
View Article and Find Full Text PDFSequencing novel agents in the treatment of classical Hodgkin lymphoma.
Expert Rev Hematol
December 2023
Introduction: Classical Hodgkin lymphoma (cHL) is a curable disease, with durable remission achieved in about 80% of patients following first-line treatment. Three new drugs were introduced to the daily use in cHL: brentuximab vedotin (BV), nivolumab, and pembrolizumab. All three drugs were initially approved for the treatment of relapsed/refractory cHL (RRHL) and with their promising outcomes, they are now incorporated in different stages of the treatment.
View Article and Find Full Text PDFIndependent risk factors for COVID-19-associated coagulopathy.
Eur Rev Med Pharmacol Sci
August 2023
Objective: Past three years since the beginning of the outbreak, we have obtained satisfactory data on COVID-19. However, data on risk factors of COVID-19-associated coagulopathy (CAC) are extremely limited. Prediction of CAC might be a game changer since it is related to poor prognosis.
View Article and Find Full Text PDFArticle Synopsis
- Glofitamab is a bi-specific antibody used to treat relapsed or refractory B-cell lymphoma, showing potential in a phase II trial, but real-world data is limited.
- A retrospective study in Turkey analyzed 43 DLBCL patients receiving glofitamab, revealing median overall survival of 8.8 months and a 1-year progression-free survival rate of 83%.
- While the treatment had promising effectiveness, toxicity was a significant concern, with deaths linked to disease progression and treatment-related side effects like cytokine release syndrome.